Search

Displaying results 1631 - 1640 of 10000 in total
  1. Drug

    Gallium citrate Ga-67

    go.drugbank.com/drugs/DB06784
    Approved

    Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation

  2. Drug

    Epicriptine

    go.drugbank.com/drugs/DB11275
    Approved

    Epicriptine differs from the alpha form on the position of one methyl group.[T195] To know more about the mixture please visit [DB01049]

  3. Drug

    Carbocromen

    go.drugbank.com/drugs/DB13279
    ApprovedWithdrawn

    Carbocromen was marketed for use in Germany as a vasodilator, however, it has been discontinued due to the risk of arrhythmia development [L5635].

    Categories: Vasodilators Used in Cardiac Diseases
  4. Drug

    Sofosbuvir

    go.drugbank.com/drugs/DB08934
    ApprovedInvestigational

    In a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Sofosbuvir as first line therapy … Both Canadian and American guidelines list Epclusa as a first line recommendation for all genotypes of HCV [L852, A19626].

  5. Drug

    Tuparstobart

    go.drugbank.com/drugs/DB19118
    Investigational

    Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS

    Synonyms: Immunoglobulin G1 [301-alanine,de-C-terminal-lysine], anti-(human lymphocyte activation gene-3 protein) (human-Mus musculus monoclonal INCAGN02385 γ1-chain), disulfide with human-Mus musculus monoclonal
  6. Drug

    Ganaxolone

    go.drugbank.com/drugs/DB05087
    ApprovedInvestigational

    [L41135] In July 2023, ganaxolone was also approved under the same brand name and for the same indication by the EMA.[L47636] … [L41130] It was approved under the brand name ZTALMY by the US FDA in March 2022 for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), becoming the first FDA-approved treatment

  7. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818] … The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions.

  8. Drug

    Flumethasone

    go.drugbank.com/drugs/DB00663
    ApprovedVet approved

    This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.

    Mixtures: LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO, LOCORTEN ANTIBIOTICO E ANTINFIAMMATORIO
  9. Drug

    Capsicum oleoresin

    go.drugbank.com/drugs/DB11131
    Approved

    Due to its analgesic properties, capsicum oleoresin is used to temporarily relieve of minor aches and pains of muscles and joints as an active ingredient in topical OTC preparations and has been studied … Capsicum oleoresin is contained in pepper sprays when suspended in water, and acts an active lachrymatory agent that induces irritation, lacrimation, pain, and temporary blindness when in contact with

  10. Drug

    Cabozantinib

    go.drugbank.com/drugs/DB08875
    ApprovedInvestigational

    [L15123] In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 … Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor.